Search Results - Robert K. Stuart

  • Showing 1 - 4 results of 4
Refine Results
  1. 1

    Lower-intensity CPX-351 plus venetoclax induction for adults with newly diagnosed AML unfit for intensive chemotherapy by Geoffrey L. Uy, Vinod Pullarkat, Praneeth Baratam, Robert K. Stuart, Roland B. Walter, Eric S. Winer, Qi Wang, Stefan Faderl, Divya Chakravarthy, Diane Menno, Ronald S. Cheung, Tara L. Lin

    Published in Blood Advances (2024-12-01)
    Get full text
    Article


  2. 2

    P517: SURVIVAL OUTCOMES WITH CPX-351 VS 7 + 3 BY BASELINE BONE MARROW BLAST PERCENTAGE IN OLDER ADULTS WITH NEWLY DIAGNOSED HIGH-RISK OR SECONDARY ACUTE MYELOID LEUKEMIA: A 5-YEAR... by Ellen Ritchie, Tara L. Lin, Laura F. Newell, Robert K. Stuart, Scott Solomon, Richard Stone, Gary Schiller, Matthew Wieduwilt, Eileen Amy Ryan, Nalina Dronamraju, Jeffrey Lancet, Jorge Cortes

    Published in HemaSphere (2023-08-01)
    Get full text
    Article


  3. 3

    A phase 1b/2 study of vosaroxin in combination with cytarabine in patients with relapsed or refractory acute myeloid leukemia by Jeffrey E. Lancet, Gail J. Roboz, Larry D. Cripe, Glenn C. Michelson, Judith A. Fox, Richard D. Leavitt, Tianling Chen, Rachael Hawtin, Adam R. Craig, Farhad Ravandi, Michael B. Maris, Robert K. Stuart, Judith E. Karp

    Published in Haematologica (2015-02-01)
    Get full text
    Article


  4. 4

    Phase 3 results for vosaroxin/cytarabine in the subset of patients ≥60 years old with refractory/early relapsed acute myeloid leukemia by Farhad Ravandi, Ellen K. Ritchie, Hamid Sayar, Jeffrey E. Lancet, Michael D. Craig, Norbert Vey, Stephen A. Strickland, Gary J. Schiller, Elias Jabbour, Arnaud Pigneux, Heinz-August Horst, Christian Récher, Virginia M. Klimek, Jorge E. Cortes, Angelo-Michele Carella, Miklos Egyed, Utz Krug, Judith A. Fox, Adam R. Craig, Renee Ward, Jennifer A. Smith, Gary Acton, Hagop M. Kantarjian, Robert K. Stuart

    Published in Haematologica (2018-11-01)
    Get full text
    Article


Search Tools: